Last reviewed · How we verify
Ketorolac Plus Tobramycin/Dexamethasone vs. Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery
This randomized controlled trial compares two regimens of topical therapy: * tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day * combination of tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day, plus Ketorolac tromethamine 0.5% (Acular®, Allergan), one drop three times/day. Patients are independently assessed by two ophthalmologists. On days 7,14,21,28 patients are evaluated for * corneal edema * conjunctival hyperemia * anterior chamber (Tyndall) reaction. The investigators purpose was to evaluate the benefit of adding a non-steroid agent to an antibiotic/steroid combination after uneventful phacoemulsification. Adopting a weekly follow-up, to gain insight into the optimal duration of postoperative treatment and to examine whether risk factors for inflammation exist.
Details
| Lead sponsor | Veroia General Hospital |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 145 |
| Start date | 2009-10 |
| Completion | 2010-01 |
Conditions
- Cataract
Interventions
- Drug: Tobramycin 0.3% - Dexamethasone 0.1%
- Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine
Primary outcomes
- Visual acuity, corneal edema, Tyndall reaction, redness — 1,7,14,28 post-operative day, Up to 28 days